Holen Sie sich die Stockscreener-App
13.88
2.66%
0.36
Handel nachbörslich:
13.88
Schlusskurs vom Vortag:
$13.52
Offen:
$13.8
24-Stunden-Volumen:
660.93K
Relative Volume:
0.96
Marktkapitalisierung:
$1.30B
Einnahmen:
Nettoeinkommen (Verlust:
KGV:
-
EPS:
-
Netto-Cashflow:
1W Leistung:
-2.25%
1M Leistung:
-25.22%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
1-Tages-Spanne:
$13.13
$14.13
1-Wochen-Bereich:
$12.34
$15.93
52-Wochen-Spanne:
$12.23
$27.00
Kardigan Inc Stock (KARD) Company Profile
Compare KARD vs VRTX, MRNA, REGN, ARGX, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
KARD
Kardigan Inc
|
13.88 | 1.30B | 0 | 0 | 0 | 0.00 |
VRTX
Vertex Pharmaceuticals Inc
|
508.75 | 128.95B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
236.50 | 94.42B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
796.34 | 81.99B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
846.27 | 53.22B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
374.08 | 42.32B | 5.76B | 514.49M | 1.10B | 4.4813 |
Kardigan Inc Stock (KARD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-10-12 | Eingeleitet | UBS | Buy |
| 2026-07-13 | Eingeleitet | JP Morgan | Overweight |
| 2026-07-13 | Eingeleitet | Jefferies | Buy |
| 2026-07-13 | Eingeleitet | Leerink Partners | Outperform |
| 2026-07-13 | Eingeleitet | TD Cowen | Buy |
Kardigan Inc Aktie (KARD) Neueste Nachrichten
A 48,368-option grant at Kardigan (KARD) vests monthly over three years. - Stock Titan
Director Kristin Marie K. Reinke is identified in Kardigan (KARD)'s initial ownership statement. - Stock Titan
Neurogene Inc. (NGNE) Stock Price & News - Syfe
Kardigan: Funded Precision Cardiology Offers More Than Pipeline Diversification - Seeking Alpha
Kardigan at Cantor conference: platform bet on heart drugs - Investing.com
Kardigan at Cantor conference: platform bet on heart drugs By Investing.com - Investing.com Canada
Kardigan at Cantor conference: platform bet on heart drugs By Investing.com - Investing.com UK
Nuvectis Pharma, Inc. (NVCT) Stock Price & News - Syfe
KARDKardigan Inc Short Interest - Finviz
Kardigan to Present at Two September Investor Conferences - Yahoo Finance
Kardigan’s Danicamtiv Heart Study Moves Forward, Keeping KARD on Investors’ Radar - TipRanks
Kardigan’s Tonlamarsen Trial Targets Severe Hypertension: What Investors Should Watch - TipRanks
KARD Should I Buy - Intellectia AI
Kardigan (NASDAQ:KARD) Price Target Cut to $46.00 by Analysts at JPMorgan Chase & Co. - marketbeat.com
Will KARD be a Portfolio Killer in August? - Zacks Investment Research
Inside cardiovascular biotech Kardigan’s June IPO - CFO Brew
Kardigan Q2 Results: EPS misses estimates by 549.3% - scanx.trade
Kardigan Reports Second Quarter 2026 Financial Results and Recent Business Updates - BioSpace
Kardigan Inc. Announces Q2 2026 Financial Results and Clinical Trial Updates - Kalkine Media
Kardigan Q2 Per-Share Loss Narrows - marketscreener.com
Kardigan, Inc. 2Q 2026: Net loss $116.2M, EPS $(4.61) — 10-Q Summary - TradingView
Earnings Flash (KARD) Kardigan Posts Q2 Loss $4.61 a Share - marketscreener.com
Kardigan: Q2 Earnings Snapshot - AOL.com
Kardigan: Q2 Earnings Snapshot - KTVB
Kardigan, Inc. (NASDAQ:KARD) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Kardigan reports Q2 2026 net loss $116.2M, cash $660.7M after IPO - TradingView
Kardigan Reports Second Quarter 2026 Financial Results and Recent Business Updates - Business Wire
Kardigan Ord Shs (KARD) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Kardigan (KARD) Institutional Ownership 2026 $KARD - marketbeat.com
KARD: NADetailed Earnings Estimates - Zacks Investment Research
Kardigan Ord Shs (KARD) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Kardigan, Inc. Revenue Breakdown – NASDAQ:KARD - TradingView
Latest KARD ETF News Today | Earnings, Events & Price Alerts - Intellectia AI
KARD|Kardigan Ord Shs|Price:21.150|Chg%:+0.410 - TradingKey
Price to earnings ratio of Kardigan, Inc. – BOATS:KARD - TradingView
Kardigan, Inc. (NASDAQ:KARD) Short Interest Up ∞ in June - MarketBeat
Hrtg Pv, L.p. Net Worth (2026) - GuruFocus
Kevin Anthony Kelly Net Worth (2026) - GuruFocus
Schf Cif 2024, L.p. Net Worth (2026) - GuruFocus
Keith Bryon Johnson Net Worth (2026) - GuruFocus
Kardigan, Inc.: Target Price Consensus and Analysts Recommendations | KARD | US4859251013 - marketscreener.com
Kardigan, Inc.: Revenue and Earnings Analysts Forecasts Revisions | KARD | US4859251013 - marketscreener.com
A Quick Look at Today's Ratings for Kardigan(KARD.US), With a Forecast Between $37 to $51 - Moomoo
Kardigan (KARD) grants 20,706 RSUs tied to Perceptive-linked director pay - Stock Titan
KARD Initiated Coverage by TD Cowen -- Price Target Announced at $46 - GuruFocus
TD Cowen initiates Kardigan stock with buy rating on cardiology pipeline - Investing.com UK
KARD Initiated Coverage by Leerink Partners -- Rating Outperform - GuruFocus
Jefferies initiates Kardigan stock with buy rating on cardiology pipeline By Investing.com - Investing.com Nigeria
KARD Initiated Coverage by JP Morgan -- Price Target Set at $51. - GuruFocus
This Fastenal Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga
Finanzdaten der Kardigan Inc-Aktie (KARD)
Es liegen keine Finanzdaten für Kardigan Inc (KARD) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
Kardigan Inc-Aktie (KARD) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| BERNS PAUL L | Director |
Jun 22 '26 |
Buy |
16.00 |
1,250,000 |
20,000,000 |
15,042,035 |
| ARCH Venture Partners XIII, LL | Director |
Jun 22 '26 |
Buy |
16.00 |
1,250,000 |
20,000,000 |
15,042,035 |
1.35%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):